Correction: SVR12 rates higher than 99% after sofosbuvir/velpatasvir combination in HCV infected patients with F0-F1 fibrosis stage: A real world experience.
作者信息
Mangia Alessandra, Piazzolla Valeria, Giannelli Anna, Visaggi Egidio, Minerva Nicola, Palmieri Vincenzo, Carraturo Immacolata, Potenza Domenico, Napoli Nicola, Lauletta Gianfranco, Tagarielli Vincenzo, Santoro Rosanna, Piccigallo Ernesto, De Gioia Sergio, Chimenti Angelo, Cuccorese Giuseppe, Metrangolo Antonio, Mazzola Michele, Agostinacchio Ernesto, Mennea Giuseppe, Sabbà Carlo, Cela Marina, Copetti Massimiliano, Losappio Ruggiero
出版信息
PLoS One. 2019 Sep 25;14(9):e0223287. doi: 10.1371/journal.pone.0223287. eCollection 2019.
Abstract
[This corrects the article DOI: 10.1371/journal.pone.0215783.].
摘要
相似文献
1
Correction: SVR12 rates higher than 99% after sofosbuvir/velpatasvir combination in HCV infected patients with F0-F1 fibrosis stage: A real world experience.
PLoS One. 2019 Sep 25;14(9):e0223287. doi: 10.1371/journal.pone.0223287. eCollection 2019.
2
Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and Cirrhosis.索磷布韦和维帕他韦联合利巴韦林或不联合利巴韦林治疗丙型肝炎病毒基因型 3 感染合并肝硬化患者的疗效。
Gastroenterology. 2018 Oct;155(4):1120-1127.e4. doi: 10.1053/j.gastro.2018.06.042. Epub 2018 Jun 27.
3
Sofosbuvir and ribavirin for genotype 2 HCV infected patients with cirrhosis: A real life experience.索磷布韦联合利巴韦林治疗肝硬化合并基因 2 型 HCV 感染患者：真实世界经验。
J Hepatol. 2017 Apr;66(4):711-717. doi: 10.1016/j.jhep.2016.12.002. Epub 2016 Dec 10.
4
Sofosbuvir With Velpatasvir in Treatment-Naive Noncirrhotic Patients With Genotype 1 to 6 Hepatitis C Virus Infection: A Randomized Trial.索磷布韦/维帕他韦在初治非肝硬化基因型 1-6 型丙型肝炎病毒感染患者中的疗效：一项随机试验。
Ann Intern Med. 2015 Dec 1;163(11):818-26. doi: 10.7326/M15-1000. Epub 2015 Nov 10.
5
Sofosbuvir/velpatasvir for 12 weeks in genotype 1-4 HCV-infected liver transplant recipients.索磷布韦/维帕他韦治疗 12 周用于基因型 1-4 型 HCV 感染的肝移植受者。
J Hepatol. 2018 Sep;69(3):603-607. doi: 10.1016/j.jhep.2018.05.039. Epub 2018 Jun 8.
6
Sofosbuvir Plus Velpatasvir Combination Therapy for Treatment-Experienced Patients With Genotype 1 or 3 Hepatitis C Virus Infection: A Randomized Trial.索磷布韦/维帕他韦联合治疗方案治疗曾接受治疗的 1 型或 3 型丙型肝炎病毒感染患者：一项随机试验。
Ann Intern Med. 2015 Dec 1;163(11):809-17. doi: 10.7326/M15-1014. Epub 2015 Nov 10.
7
Sofosbuvir/Velpatasvir: The First Pangenotypic Direct-Acting Antiviral Combination for Hepatitis C.索磷布韦/维帕他韦：首款用于丙型肝炎的泛基因型直接抗病毒联合疗法
Ann Pharmacother. 2017 Jan;51(1):44-53. doi: 10.1177/1060028016668897. Epub 2016 Oct 1.
8
Sofosbuvir-velpatasvir single-tablet regimen administered for 12 weeks in a phase 3 study with minimal monitoring in India.在印度进行的一项 3 期研究中，使用索磷布韦-维帕他韦单片制剂进行了 12 周的治疗，监测非常少。
Hepatol Int. 2019 Mar;13(2):173-179. doi: 10.1007/s12072-019-09927-6. Epub 2019 Feb 21.
9
Sofosbuvir/velpatasvir for the treatment of HCV: excellent results from a phase-3, open-label study in Russia and Sweden.索磷布韦/维帕他韦治疗丙型肝炎病毒：俄罗斯和瑞典开放标签 3 期研究的优异结果。
Infect Dis (Lond). 2019 Feb;51(2):131-139. doi: 10.1080/23744235.2018.1535186. Epub 2018 Nov 30.
10
Real world experience with the all-oral interferon free regimen for the treatment of chronic hepatitis c virus infection in the Lebanese population.黎巴嫩人群中使用全口服无干扰素方案治疗慢性丙型肝炎病毒感染的真实世界经验。
J Infect Dev Ctries. 2018 Feb 22;12(2.1):30S. doi: 10.3855/jidc.10028.
引用本文的文献
1
Hepatitis C and Thalassemia: A Story with (Almost) a Happy Ending.丙型肝炎与地中海贫血：一个（几乎）有美满结局的故事。
Pathogens. 2023 May 5;12(5):683. doi: 10.3390/pathogens12050683.
2
Directly observed therapy at opioid substitution facilities using sofosbuvir/velpatasvir results in excellent SVR12 rates in PWIDs at high risk for non-adherence to DAA therapy.在阿片类药物替代治疗机构中使用索磷布韦/维帕他韦进行直接观察治疗，可使高不依从 DAA 治疗风险的药物使用障碍者获得极佳的 SVR12 率。
PLoS One. 2021 Jun 4;16(6):e0252274. doi: 10.1371/journal.pone.0252274. eCollection 2021.
3
Sofosbuvir/velpatasvir in treatment-experienced HCV-infected patients - short report.索磷布韦/维帕他韦用于经治丙型肝炎病毒感染患者——简短报告
Clin Exp Hepatol. 2020 Feb;6(1):60-62. doi: 10.5114/ceh.2020.93059. Epub 2020 Feb 17.
本文引用的文献
1
SVR12 rates higher than 99% after sofosbuvir/velpatasvir combination in HCV infected patients with F0-F1 fibrosis stage: A real world experience.索磷布韦/维帕他韦联合治疗 F0-F1 纤维化期 HCV 感染患者的 SVR12 率高于 99%：真实世界经验。
PLoS One. 2019 May 15;14(5):e0215783. doi: 10.1371/journal.pone.0215783. eCollection 2019.
Zotero 插件